GlassScriptPhysician profile
Deepak Bacharanianda Muthappa
NPI 1831532241
$84,128.24
in general payments reported to CMS, 2019-2025
52 companies · $22K in 2025
The $22K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,763 · 2020: $9,547 · 2021: $15K · 2022: $12K · 2023: $9,594 · 2024: $14K · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31K · Consulting Fee: $6,844 · Food and Beverage: $5,973 · Travel and Lodging: $2,045 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30,937.50 |
| Consulting Fee | $6,843.75 |
| Food and Beverage | $5,972.54 |
| Travel and Lodging | $2,045.35 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $62,113.16 | 2021-2025 | |
| Allergan, INC. | $11,534.38 | 2019-2021 | |
| Novo Nordisk INC | $1,555.18 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,291.04 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,142.82 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $835.50 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Merck Sharp & Dohme LLC | $534.74 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $474.53 | 2021-2025 | Repatha, Otezla, Repatha |
| Mylan Specialty L.P. | $469.23 | 2019-2023 | Yupelri |
| Pfizer INC. | $386.48 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $348.32 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $302.39 | 2020-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $287.77 | 2019-2024 | Xarelto, Spravato |
| Sanofi-Aventis U.S. LLC | $282.59 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.37 | 2019-2025 | Jardiance, Synjardy |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Muthappa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.